Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:2164329.
doi: 10.1155/2016/2164329. Epub 2016 Jun 29.

Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban

Ana Boban  1 , Catherine Lambert  2 , Cedric Hermans  2
Affiliations

Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban

Ana Boban et al. Case Rep Hematol. 2016.

Abstract

We here present the successful initial treatment and secondary prophylaxis of superficial venous thrombosis secondary to Behçet's disease by a novel anticoagulant drug, rivaroxaban (Xarelto®). To our knowledge, this is the first case of using an oral direct inhibitor of FXa in this setting. Our findings are promising; the outcome was favourable without any adverse effect noted. We propose that the patients with Behçet's disease and venous thrombosis might benefit from the advantages of the new anticoagulant drug.

PubMed Disclaimer

References

    1. Sakane T., Takeno M., Suzuki N., Inaba G. Behcet's disease. The New England Journal of Medicine. 1999;341(17):1284–1291. doi: 10.1056/nejm199910213411707. - DOI - PubMed
    1. Desbois A. C., Wechsler B., Resche-Rigon M., et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis and Rheumatism. 2012;64(8):2753–2760. doi: 10.1002/art.34450. - DOI - PubMed
    1. Ahn J. K., Lee Y. S., Jeon C. H., Koh E.-M., Cha H.-S. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clinical Rheumatology. 2008;27(2):201–205. doi: 10.1007/s10067-007-0685-z. - DOI - PubMed
    1. Kiraz S., Ertenli I., Öztürk M. A., Haznedarolu I. C., Çelik I., Çalgüneri M. Pathological haemostasis and ‘prothrombotic state’ in Behçet's disease. Thrombosis Research. 2002;105(2):125–133. doi: 10.1016/s0049-3848(02)00006-3. - DOI - PubMed
    1. Saadoun D., Wechsler B., Desseaux K., et al. Mortality in Behçet's disease. Arthritis and Rheumatism. 2010;62(9):2806–2812. doi: 10.1002/art.27568. - DOI - PubMed

LinkOut - more resources